Thermo Fisher Scientific Inc. (0R0H.L)
USD 447.96
(0.78%)
USD 447.96
(0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 10.8 Billion USD | -11.05% |
| 2022 | 11.94 Billion USD | -0.9% |
| 2021 | 12.96 Billion USD | 19.25% |
| 2020 | 10.19 Billion USD | 54.34% |
| 2019 | 6.46 Billion USD | 5.83% |
| 2018 | 6.19 Billion USD | 21.26% |
| 2017 | 5.25 Billion USD | 16.0% |
| 2016 | 4.25 Billion USD | 6.88% |
| 2015 | 4.03 Billion USD | 13.71% |
| 2014 | 4.25 Billion USD | 37.4% |
| 2013 | 2.58 Billion USD | 3.2% |
| 2012 | 2.49 Billion USD | 15.24% |
| 2011 | 2.18 Billion USD | 6.08% |
| 2010 | 1.91 Billion USD | 10.18% |
| 2009 | 1.83 Billion USD | -8.66% |
| 2008 | 2.07 Billion USD | 15.21% |
| 2007 | 1.77 Billion USD | 217.24% |
| 2006 | 502.07 Million USD | 49.56% |
| 2005 | 435.88 Million USD | 22.18% |
| 2004 | 336.33 Million USD | 2.19% |
| 2003 | 279.3 Million USD | 58.94% |
| 2002 | 193.07 Million USD | -46.61% |
| 2001 | 265.42 Million USD | 17.05% |
| 2000 | 295.64 Million USD | -46.11% |
| 1999 | 362.2 Million USD | 9.74% |
| 1998 | 353.4 Million USD | 13.22% |
| 1997 | 371.6 Million USD | 49.37% |
| 1996 | 399.4 Million USD | 52.02% |
| 1995 | 332.3 Million USD | 27.96% |
| 1994 | 242.1 Million USD | 0.19% |
| 1993 | 166 Million USD | 301.27% |
| 1992 | 97.5 Million USD | 1545.83% |
| 1991 | 61.7 Million USD | 13.42% |
| 1990 | 54.4 Million USD | 78.36% |
| 1989 | 30.5 Million USD | 0.66% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.55 Billion USD | -10.77% |
| 2024 Q3 | 1.83 Billion USD | -2.38% |
| 2024 Q2 | 2.54 Billion USD | 16.24% |
| 2023 Q2 | 2.79 Billion USD | 6.07% |
| 2023 Q3 | 3.06 Billion USD | 9.56% |
| 2023 Q4 | 1.85 Billion USD | -39.43% |
| 2023 FY | - USD | -11.05% |
| 2023 Q1 | 2.63 Billion USD | -10.68% |
| 2022 Q4 | 2.94 Billion USD | 11.49% |
| 2022 Q1 | 3.53 Billion USD | 28.52% |
| 2022 Q2 | 2.92 Billion USD | -17.3% |
| 2022 FY | - USD | -0.9% |
| 2022 Q3 | 2.64 Billion USD | -9.57% |
| 2021 FY | - USD | 19.25% |
| 2021 Q1 | 3.51 Billion USD | -4.33% |
| 2021 Q2 | 2.94 Billion USD | -16.08% |
| 2021 Q3 | 2.94 Billion USD | -0.03% |
| 2021 Q4 | 2.75 Billion USD | -6.62% |
| 2020 Q1 | 1.56 Billion USD | -12.27% |
| 2020 Q4 | 3.67 Billion USD | 22.89% |
| 2020 Q2 | 1.97 Billion USD | 26.18% |
| 2020 FY | - USD | 54.34% |
| 2020 Q3 | 2.98 Billion USD | 51.21% |
| 2019 Q1 | 1.57 Billion USD | -10.53% |
| 2019 Q2 | 1.66 Billion USD | 5.66% |
| 2019 Q3 | 1.59 Billion USD | -4.15% |
| 2019 Q4 | 1.78 Billion USD | 12.12% |
| 2019 FY | - USD | 5.83% |
| 2018 Q1 | 1.41 Billion USD | -9.25% |
| 2018 Q4 | 1.75 Billion USD | 16.51% |
| 2018 FY | - USD | 21.26% |
| 2018 Q3 | 1.5 Billion USD | -3.58% |
| 2018 Q2 | 1.56 Billion USD | 10.37% |
| 2017 Q3 | 1.2 Billion USD | -4.5% |
| 2017 Q1 | 1.12 Billion USD | -13.71% |
| 2017 Q2 | 1.25 Billion USD | 11.86% |
| 2017 Q4 | 1.56 Billion USD | 29.78% |
| 2017 FY | - USD | 16.0% |
| 2016 FY | - USD | 6.88% |
| 2016 Q1 | 995.9 Million USD | -13.97% |
| 2016 Q3 | 1.02 Billion USD | -7.32% |
| 2016 Q4 | 1.3 Billion USD | 26.84% |
| 2016 Q2 | 1.11 Billion USD | 11.5% |
| 2015 FY | - USD | 13.71% |
| 2015 Q1 | 938.7 Million USD | -15.86% |
| 2015 Q2 | 1.04 Billion USD | 11.49% |
| 2015 Q3 | 1.01 Billion USD | -3.32% |
| 2015 Q4 | 1.15 Billion USD | 14.4% |
| 2014 Q4 | 1.11 Billion USD | 11.45% |
| 2014 Q1 | 675.6 Million USD | -6.06% |
| 2014 Q2 | 861.3 Million USD | 27.49% |
| 2014 Q3 | 1 Billion USD | 16.23% |
| 2014 FY | - USD | 37.4% |
| 2013 Q2 | 615.1 Million USD | -9.52% |
| 2013 Q1 | 679.8 Million USD | -2.23% |
| 2013 FY | - USD | 3.2% |
| 2013 Q4 | 719.2 Million USD | 11.49% |
| 2013 Q3 | 645.1 Million USD | 4.88% |
| 2012 Q3 | 618.5 Million USD | -3.22% |
| 2012 Q2 | 639.1 Million USD | 3.05% |
| 2012 Q1 | 620.2 Million USD | -1.74% |
| 2012 FY | - USD | 15.24% |
| 2012 Q4 | 695.3 Million USD | 12.42% |
| 2011 Q4 | 631.2 Million USD | 11.95% |
| 2011 Q1 | 526.1 Million USD | -6.09% |
| 2011 Q2 | 514.9 Million USD | -2.13% |
| 2011 Q3 | 563.8 Million USD | 9.5% |
| 2011 FY | - USD | 6.08% |
| 2010 FY | - USD | 10.18% |
| 2010 Q4 | 560.2 Million USD | 7.57% |
| 2010 Q3 | 520.8 Million USD | 1.26% |
| 2010 Q2 | 514.3 Million USD | 0.35% |
| 2010 Q1 | 512.5 Million USD | -8.3% |
| 2009 Q4 | 558.9 Million USD | 27.23% |
| 2009 FY | - USD | -8.66% |
| 2009 Q2 | 421.1 Million USD | 5.46% |
| 2009 Q3 | 439.3 Million USD | 4.32% |
| 2009 Q1 | 399.3 Million USD | -29.06% |
| 2008 Q4 | 562.9 Million USD | 8.31% |
| 2008 FY | - USD | 15.21% |
| 2008 Q1 | 491.5 Million USD | -6.08% |
| 2008 Q2 | 520.4 Million USD | 5.88% |
| 2008 Q3 | 519.7 Million USD | -0.13% |
| 2007 Q1 | 390.9 Million USD | 80.2% |
| 2007 Q4 | 523.3 Million USD | 14.01% |
| 2007 FY | - USD | 217.24% |
| 2007 Q2 | 444.8 Million USD | 13.79% |
| 2007 Q3 | 459 Million USD | 3.19% |
| 2006 FY | - USD | 49.56% |
| 2006 Q1 | 111.86 Million USD | -16.92% |
| 2006 Q3 | 124.58 Million USD | 4.09% |
| 2006 Q4 | 216.92 Million USD | 74.12% |
| 2006 Q2 | 119.69 Million USD | 6.99% |
| 2005 Q4 | 134.65 Million USD | 14.48% |
| 2005 FY | - USD | 22.18% |
| 2005 Q3 | 117.62 Million USD | 105.55% |
| 2005 Q2 | 57.22 Million USD | -22.22% |
| 2005 Q1 | 73.57 Million USD | -22.16% |
| 2004 Q3 | 83.28 Million USD | 33.25% |
| 2004 Q1 | 79.53 Million USD | -24.07% |
| 2004 FY | - USD | 2.19% |
| 2004 Q4 | 94.52 Million USD | 13.5% |
| 2004 Q2 | 62.5 Million USD | -21.42% |
| 2003 Q2 | 62.64 Million USD | -2.75% |
| 2003 Q3 | 61.34 Million USD | 19.87% |
| 2003 Q4 | 91.23 Million USD | 39.5% |
| 2003 Q1 | 61.43 Million USD | -15.0% |
| 2003 FY | - USD | 58.94% |
| 2002 FY | - USD | -46.61% |
| 2002 Q3 | 65.6 Million USD | 43.12% |
| 2002 Q2 | 44.1 Million USD | 337.69% |
| 2002 Q1 | 59.65 Million USD | -91.94% |
| 2002 Q4 | 74.21 Million USD | 20.06% |
| 2001 Q4 | 64.55 Million USD | 94.24% |
| 2001 FY | - USD | 17.05% |
| 2001 Q3 | 63.75 Million USD | -23.93% |
| 2001 Q2 | 62.45 Million USD | -3.58% |
| 2001 Q1 | 74.66 Million USD | -35.35% |
| 2000 Q4 | 65.51 Million USD | 569.9% |
| 2000 FY | - USD | -46.11% |
| 2000 Q3 | 59.38 Million USD | -77.48% |
| 2000 Q1 | 73.72 Million USD | 167.33% |
| 2000 Q2 | 77.87 Million USD | 0.75% |
| 1999 Q2 | 106.23 Million USD | 457.43% |
| 1999 FY | - USD | 9.74% |
| 1999 Q1 | 78.65 Million USD | -54.84% |
| 1999 Q4 | 11.1 Million USD | -212.76% |
| 1999 Q3 | 95.03 Million USD | -76.43% |
| 1998 FY | - USD | 13.22% |
| 1998 Q1 | 130.6 Million USD | -49.42% |
| 1998 Q2 | 146 Million USD | 88.6% |
| 1998 Q3 | 142.1 Million USD | 23.77% |
| 1998 Q4 | 121.1 Million USD | 29.04% |
| 1997 FY | - USD | 49.37% |
| 1997 Q4 | 156.9 Million USD | -7.8% |
| 1997 Q3 | 152.4 Million USD | 67.98% |
| 1997 Q2 | 84 Million USD | 109.48% |
| 1997 Q1 | 40.1 Million USD | -41.97% |
| 1996 FY | - USD | 52.02% |
| 1996 Q1 | 8.2 Million USD | -77.9% |
| 1996 Q4 | 69.1 Million USD | 54.24% |
| 1996 Q2 | 16.9 Million USD | 106.1% |
| 1996 Q3 | 44.8 Million USD | 165.09% |
| 1995 Q2 | 30.7 Million USD | 46.19% |
| 1995 Q4 | 37.1 Million USD | 25.76% |
| 1995 Q3 | 29.5 Million USD | -3.91% |
| 1995 Q1 | 21 Million USD | -40.34% |
| 1995 FY | - USD | 27.96% |
| 1994 Q2 | 15.9 Million USD | -25.7% |
| 1994 Q3 | 24.3 Million USD | 52.83% |
| 1994 Q4 | 35.2 Million USD | 44.86% |
| 1994 FY | - USD | 0.19% |
| 1994 Q1 | 21.4 Million USD | -67.96% |
| 1993 Q2 | 8.5 Million USD | -69.42% |
| 1993 Q4 | 38 Million USD | 137.72% |
| 1993 Q1 | 36.7 Million USD | 9366.67% |
| 1993 Q3 | 28.1 Million USD | 230.59% |
| 1993 FY | - USD | 301.27% |
| 1992 Q3 | 13.1 Million USD | 254.05% |
| 1992 Q4 | -300 Thousand USD | -102.29% |
| 1992 Q1 | -6.2 Million USD | 47.46% |
| 1992 Q2 | 3.7 Million USD | 159.68% |
| 1992 FY | - USD | 1545.83% |
| 1991 Q3 | -7.2 Million USD | -111.76% |
| 1991 Q4 | -11.8 Million USD | -63.89% |
| 1991 Q1 | -200 Thousand USD | -104.08% |
| 1991 FY | - USD | -86.59% |
| 1991 Q2 | -3.4 Million USD | -1600.0% |
| 1990 Q3 | 4.8 Million USD | 181.36% |
| 1990 Q4 | 4.9 Million USD | 2.08% |
| 1990 Q1 | 9.3 Million USD | 203.23% |
| 1990 Q2 | 6.6 Million USD | -284.38% |
| 1990 FY | - USD | 2337.5% |
| 1989 Q1 | 137.2 Million USD | 141.44% |
| 1989 FY | - USD | -108.16% |
| 1989 Q4 | 7 Million USD | -3.33% |
| 1989 Q2 | 150.8 Million USD | 9.91% |
| 1989 Q3 | 6.2 Million USD | -101.99% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 4367.088% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 4160.196% |
| bluebird bio, Inc. | -167.16 Million USD | 6560.837% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 9279.771% |
| Editas Medicine, Inc. | -163.11 Million USD | 6721.014% |
| IQVIA Holdings Inc. | 3.25 Billion USD | -231.695% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -827.798% |
| Myriad Genetics, Inc. | -67.8 Million USD | 16029.204% |
| Biogen Inc. | 2.37 Billion USD | -354.354% |
| Nektar Therapeutics | -243.1 Million USD | 4542.488% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 3226.221% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 11829.059% |
| Imunon, Inc. | -20.78 Million USD | 52067.362% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -2495.53% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -10891.024% |
| Verastem, Inc. | -83.16 Million USD | 13086.076% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 195.762% |
| Waters Corporation | 1.02 Billion USD | -956.492% |
| Perrigo Company plc | 646.2 Million USD | -1571.309% |
| Dynavax Technologies Corporation | 9.66 Million USD | -111631.844% |
| Illumina, Inc. | -608 Million USD | 1876.316% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 24404.235% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 2505.276% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 10505.426% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 29067.626% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -3380.682% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 12453.163% |
| Evolus, Inc. | -41.81 Million USD | 25931.141% |
| Adicet Bio, Inc. | -136.53 Million USD | 8010.06% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 12374.82% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | -132.048% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 7294.82% |
| FibroGen, Inc. | -261.4 Million USD | 4231.52% |
| Agilent Technologies, Inc. | 1.67 Billion USD | -544.007% |
| OPKO Health, Inc. | -65.51 Million USD | 16584.523% |
| Homology Medicines, Inc. | -47.75 Million USD | 22714.959% |
| Geron Corporation | -174.78 Million USD | 6279.126% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 4834.33% |
| Exelixis, Inc. | 196.6 Million USD | -5393.332% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 10811.417% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 19470.113% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 2233.059% |
| Zoetis Inc. | 3.68 Billion USD | -193.08% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 4900.192% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 21455.691% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | -134.518% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 30031.822% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 4795.448% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 2559.039% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -9870.09% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -2289.661% |
| Blueprint Medicines Corporation | -474.61 Million USD | 2375.543% |
| Insmed Incorporated | -654.73 Million USD | 1749.512% |
| TG Therapeutics, Inc. | 26.1 Million USD | -41279.31% |
| Incyte Corporation | 919.42 Million USD | -1074.646% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 2237.344% |